A carregar...

A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy

This dose-ranging study was conducted to identify the optimal fixed dose of lipegfilgrastim compared with pegfilgrastim 6.0 mg for the provision of neutrophil support during myelosuppressive chemotherapy in patients with breast cancer. A phase 2 study was conducted in which 208 chemotherapy-naive pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Buchner, Anton, Elsässer, Reiner, Bias, Peter
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2014
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4196040/
https://ncbi.nlm.nih.gov/pubmed/25261291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3120-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!